Skip to main content
Top
Published in: Arthritis Research & Therapy 1/2020

01-12-2020 | Systemic Lupus Erythematosus | Research article

Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study

Authors: Worawit Louthrenoo, Nuntana Kasitanon, Eric Morand, Rangi Kandane-Rathnayake

Published in: Arthritis Research & Therapy | Issue 1/2020

Login to get access

Abstract

Background

The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. We compared the performance of generic (SF36) and specific (SLEQOL) HRQoL surveys by examining their associations with the Global Rating of Change (GRC) and SLE clinical indicators.

Methods

The study included SLE patients who attended a single-center rheumatology clinic between 2013 and 2017. Patients completed both specific (SLEQOL) and generic (SF36) surveys and rated their GRC compared to the previous visit using a 7-point Likert scale on the same day of routine visits. Based on GRC scores, patients’ change in HRQoL was categorized as “no change,” “deterioration,” or “improvement.” Disease activity (SLEDAI-2K), flare, and lupus low disease activity state (LLDAS) were assessed at each visit, and organ damage (SDI) was determined annually. Pairwise correlations between SLEQOL and SF36 components were examined, and associations between GRC status and SLE disease indicators were compared using generalized estimating equations (GEE).

Results

Three hundred thirty-seven patients with 2062 visits were included in the analysis. SLEQOL correlated significantly with SF36. Patients reported improvements in HRQoL in 58%, deterioration in 15%, and “no change” in 27% of all visits. Compared to the “no change” group, mean SF36 and SLEQOL scores were significantly lower in the deterioration group and higher in the improvement group. The magnitude of changes observed with SLEQOL and SF36 in the deterioration and improvement groups was similar. Patients in LLDAS had significantly higher mean scores in both SLEQOL and SF36. In contrast, patients with active disease, especially those with cutaneous, renal, central nervous system, and musculoskeletal activity, had significantly lower SLEQOL and SF36. Flare and organ damage were also associated with lower SLEQOL and SF36-PCS (physical component) but not with SF36-MCS (mental component).

Conclusion

SLEQOL and SF36 similarly describe HRQoL in SLE. Both instruments demonstrated strong associations with GRC-based deterioration or improvement as well as SLE disease status. LLDAS was associated with improved HRQoL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159–68.PubMedCrossRef Jakes RW, Bae SC, Louthrenoo W, Mok CC, Navarra SV, Kwon N. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken). 2012;64(2):159–68.PubMedCrossRef
3.
go back to reference Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4(1):e000239.PubMedPubMedCentralCrossRef Touma Z, Gladman DD. Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. Lupus Sci Med. 2017;4(1):e000239.PubMedPubMedCentralCrossRef
4.
go back to reference Phuti A, Schneider M, Tikly M, Hodkinson B. Living with systemic lupus erythematosus in the developing world. Rheumatol Int. 2018;38(9):1601–13.PubMedCrossRef Phuti A, Schneider M, Tikly M, Hodkinson B. Living with systemic lupus erythematosus in the developing world. Rheumatol Int. 2018;38(9):1601–13.PubMedCrossRef
5.
go back to reference Last JM. Dictionary of epidemiology. New York: Oxford University Press; 1995. Last JM. Dictionary of epidemiology. New York: Oxford University Press; 1995.
6.
go back to reference Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology Lupus. 2000;9(5):322–7.PubMed Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology Lupus. 2000;9(5):322–7.PubMed
7.
go back to reference Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76.CrossRef Leong KP, Kong KO, Thong BY, Koh ET, Lian TY, Teh CL, et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology (Oxford). 2005;44(10):1267–76.CrossRef
8.
go back to reference Aziz MM, Galal MAA, Elzohri MH, El-Nouby F, Leong KP. Cross-cultural adaptation and validation of Systemic Lupus Erythematosus Quality of Life questionnaire into Arabic. Lupus. 2018;27(5):780–7.PubMedCrossRef Aziz MM, Galal MAA, Elzohri MH, El-Nouby F, Leong KP. Cross-cultural adaptation and validation of Systemic Lupus Erythematosus Quality of Life questionnaire into Arabic. Lupus. 2018;27(5):780–7.PubMedCrossRef
9.
go back to reference Jiang HZ, Lin ZG, Li HJ, Du Q, Tian W, Wang SY, et al. The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37(1):151–60.PubMedCrossRef Jiang HZ, Lin ZG, Li HJ, Du Q, Tian W, Wang SY, et al. The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. Clin Rheumatol. 2018;37(1):151–60.PubMedCrossRef
10.
go back to reference McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972–9.PubMedCrossRef McElhone K, Abbott J, Shelmerdine J, Bruce IN, Ahmad Y, Gordon C, et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007;57(6):972–9.PubMedCrossRef
11.
go back to reference Conti F, Perricone C, Reboldi G, Gawlicki M, Bartosiewicz I, Pacucci VA, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014;23(8):743–51.PubMedCrossRef Conti F, Perricone C, Reboldi G, Gawlicki M, Bartosiewicz I, Pacucci VA, et al. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus. 2014;23(8):743–51.PubMedCrossRef
12.
go back to reference Wang SL, Wu B, Leng L, Bucala R, Lu LJ. Validity of LupusQoL-China for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosus. PLoS One. 2013;8(5):e63795.PubMedPubMedCentralCrossRef Wang SL, Wu B, Leng L, Bucala R, Lu LJ. Validity of LupusQoL-China for the assessment of health related quality of life in Chinese patients with systemic lupus erythematosus. PLoS One. 2013;8(5):e63795.PubMedPubMedCentralCrossRef
13.
go back to reference Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012;42(1):56–65.PubMedCrossRef Jolly M, Pickard AS, Block JA, Kumar RB, Mikolaitis RA, Wilke CT, et al. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012;42(1):56–65.PubMedCrossRef
14.
go back to reference Navarra SV, Tanangunan RM, Mikolaitis-Preuss RA, Kosinski M, Block JA, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus. 2013;22(3):262–7.PubMedCrossRef Navarra SV, Tanangunan RM, Mikolaitis-Preuss RA, Kosinski M, Block JA, Jolly M. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines. Lupus. 2013;22(3):262–7.PubMedCrossRef
15.
go back to reference Kaya A, Goker B, Cura ES, Tezcan ME, Tufan A, Mercan R, et al. Turkish lupusPRO: cross-cultural validation study for lupus. Clin Rheumatol. 2014;33(8):1079–84.PubMedCrossRef Kaya A, Goker B, Cura ES, Tezcan ME, Tufan A, Mercan R, et al. Turkish lupusPRO: cross-cultural validation study for lupus. Clin Rheumatol. 2014;33(8):1079–84.PubMedCrossRef
16.
go back to reference Mok CC, Kosinski M, Ho LY, Chan KL, Jolly M. Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(2):297–304.CrossRef Mok CC, Kosinski M, Ho LY, Chan KL, Jolly M. Validation of the LupusPRO in Chinese patients from Hong Kong with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2015;67(2):297–304.CrossRef
17.
go back to reference Inoue M, Shiozawa K, Yoshihara R, Yamane T, Shima Y, Hirano T, et al. The Japanese LupusPRO: a cross-cultural validation of an outcome measure for lupus. Lupus. 2017;26(8):849–56.PubMedCrossRef Inoue M, Shiozawa K, Yoshihara R, Yamane T, Shima Y, Hirano T, et al. The Japanese LupusPRO: a cross-cultural validation of an outcome measure for lupus. Lupus. 2017;26(8):849–56.PubMedCrossRef
18.
go back to reference Grootscholten C, Ligtenberg G, Derksen RH, Schreurs KM, de Glas-Vos JW, Hagen EC, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12(6):635–44.PubMedCrossRef Grootscholten C, Ligtenberg G, Derksen RH, Schreurs KM, de Glas-Vos JW, Hagen EC, et al. Health-related quality of life in patients with systemic lupus erythematosus: development and validation of a lupus specific symptom checklist. Qual Life Res. 2003;12(6):635–44.PubMedCrossRef
19.
go back to reference Freire EA, Guimaraes E, Maia I, Ciconelli RM. Systemic lupus erythematosus symptom checklist cross-cultural adaptation to Brazilian Portuguese language and reliability evaluation. Acta Reumatol Port. 2007;32(4):341–4.PubMed Freire EA, Guimaraes E, Maia I, Ciconelli RM. Systemic lupus erythematosus symptom checklist cross-cultural adaptation to Brazilian Portuguese language and reliability evaluation. Acta Reumatol Port. 2007;32(4):341–4.PubMed
20.
go back to reference Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68(2):196–200.PubMedCrossRef Doward LC, McKenna SP, Whalley D, Tennant A, Griffiths B, Emery P, et al. The development of the L-QoL: a quality-of-life instrument specific to systemic lupus erythematosus. Ann Rheum Dis. 2009;68(2):196–200.PubMedCrossRef
21.
go back to reference Duruoz MT, Unal C, Toprak CS, Sezer I, Yilmaz F, Ulutatar F, et al. The validity and reliability of Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) in a Turkish population. Lupus. 2017;26(14):1528–33.PubMedCrossRef Duruoz MT, Unal C, Toprak CS, Sezer I, Yilmaz F, Ulutatar F, et al. The validity and reliability of Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL) in a Turkish population. Lupus. 2017;26(14):1528–33.PubMedCrossRef
22.
go back to reference Baba S, Katsumata Y, Okamoto Y, Kawaguchi Y, Hanaoka M, Kawasumi H, et al. Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study. Lupus. 2018;27(3):407–16.PubMedCrossRef Baba S, Katsumata Y, Okamoto Y, Kawaguchi Y, Hanaoka M, Kawasumi H, et al. Reliability of the SF-36 in Japanese patients with systemic lupus erythematosus and its associations with disease activity and damage: a two-consecutive year prospective study. Lupus. 2018;27(3):407–16.PubMedCrossRef
23.
go back to reference Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford). 2015;54(5):940–9.CrossRef Devilliers H, Amoura Z, Besancenot JF, Bonnotte B, Pasquali JL, Wahl D, et al. Responsiveness of the 36-item Short Form Health Survey and the Lupus Quality of Life questionnaire in SLE. Rheumatology (Oxford). 2015;54(5):940–9.CrossRef
24.
go back to reference Wang SL, Wu B, Zhu LA, Leng L, Bucala R, Lu LJ. Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS One. 2014;9(6):e98883.PubMedPubMedCentralCrossRef Wang SL, Wu B, Zhu LA, Leng L, Bucala R, Lu LJ. Construct and criterion validity of the Euro Qol-5D in patients with systemic lupus erythematosus. PLoS One. 2014;9(6):e98883.PubMedPubMedCentralCrossRef
25.
go back to reference Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16.PubMedCrossRef Aggarwal R, Wilke CT, Pickard AS, Vats V, Mikolaitis R, Fogg L, et al. Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. J Rheumatol. 2009;36(6):1209–16.PubMedCrossRef
26.
go back to reference Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMedCrossRef Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725.PubMedCrossRef
27.
go back to reference Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.PubMedPubMedCentralCrossRef Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–86.PubMedPubMedCentralCrossRef
28.
go back to reference Kasitanon N, Wangkaew S, Puntana S, Sukitawut W, Leong KP, Tan Tock Seng Hospital Lupus Study G, et al. The reliability, validity and responsiveness of the Thai version of Systemic Lupus Erythematosus Quality of Life (SLEQOL-TH) instrument. Lupus. 2013;22(3):289–96.PubMedCrossRef Kasitanon N, Wangkaew S, Puntana S, Sukitawut W, Leong KP, Tan Tock Seng Hospital Lupus Study G, et al. The reliability, validity and responsiveness of the Thai version of Systemic Lupus Erythematosus Quality of Life (SLEQOL-TH) instrument. Lupus. 2013;22(3):289–96.PubMedCrossRef
29.
go back to reference Jirarattanaphochai K, Jung S, Sumananont C, Saengnipanthkul S. Reliability of the medical outcomes study short-form survey version 2.0 (Thai version) for the evaluation of low back pain patients. J Med Assoc Thail. 2005;88(10):1355–61. Jirarattanaphochai K, Jung S, Sumananont C, Saengnipanthkul S. Reliability of the medical outcomes study short-form survey version 2.0 (Thai version) for the evaluation of low back pain patients. J Med Assoc Thail. 2005;88(10):1355–61.
30.
go back to reference Trathitiphan W, Paholpak P, Sirichativapee W, Wisanuyotin T, Laupattarakasem P, Sukhonthamarn K, et al. Cross-cultural adaptation and validation of the reliability of the Thai version of the Hip disability and Osteoarthritis Outcome Score (HOOS). Rheumatol Int. 2016;36(10):1455–8.PubMedCrossRef Trathitiphan W, Paholpak P, Sirichativapee W, Wisanuyotin T, Laupattarakasem P, Sukhonthamarn K, et al. Cross-cultural adaptation and validation of the reliability of the Thai version of the Hip disability and Osteoarthritis Outcome Score (HOOS). Rheumatol Int. 2016;36(10):1455–8.PubMedCrossRef
31.
go back to reference Kongsaengdao S, Maneeton N, Maneeton B. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Neuropsychiatr Dis Treat. 2018;14:1119–24.PubMedPubMedCentralCrossRef Kongsaengdao S, Maneeton N, Maneeton B. Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study. Neuropsychiatr Dis Treat. 2018;14:1119–24.PubMedPubMedCentralCrossRef
32.
go back to reference Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.PubMed Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288–91.PubMed
33.
go back to reference Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51.PubMedPubMedCentralCrossRef Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61(9):1143–51.PubMedPubMedCentralCrossRef
34.
go back to reference Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685–91.PubMedCrossRef Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685–91.PubMedCrossRef
35.
go back to reference Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):809–13.PubMedCrossRef Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997;40(5):809–13.PubMedCrossRef
36.
go back to reference Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–21.PubMedCrossRef Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016;75(9):1615–21.PubMedCrossRef
37.
go back to reference Bell ML, King MT. Analysis, reporting and interpretation of health-related quality of life: a Quality of Life Office position paper. The Psycho-Oncology Co-operative Research Group, The Quality of Life Office, School of Psychology, The University of Sydney, Australia. http://www.pocog.org.au/docview.aspx?id=293. Assessed 28 July 2018. 2006. Bell ML, King MT. Analysis, reporting and interpretation of health-related quality of life: a Quality of Life Office position paper. The Psycho-Oncology Co-operative Research Group, The Quality of Life Office, School of Psychology, The University of Sydney, Australia. http://​www.​pocog.​org.​au/​docview.​aspx?​id=​293. Assessed 28 July 2018. 2006.
38.
go back to reference Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81–7.PubMedCrossRef Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47(1):81–7.PubMedCrossRef
39.
go back to reference Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005;32(5):824–7.PubMed Ibanez D, Gladman DD, Urowitz MB. Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. J Rheumatol. 2005;32(5):824–7.PubMed
40.
go back to reference Golder V, Ooi JJY, Antony AS, Ko T, Morton S, Kandane-Rathnayake R, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2018;27(3):501–6.PubMedCrossRef Golder V, Ooi JJY, Antony AS, Ko T, Morton S, Kandane-Rathnayake R, et al. Discordance of patient and physician health status concerns in systemic lupus erythematosus. Lupus. 2018;27(3):501–6.PubMedCrossRef
41.
go back to reference Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163–70.PubMedPubMedCentralCrossRef Kamper SJ, Maher CG, Mackay G. Global rating of change scales: a review of strengths and weaknesses and considerations for design. J Man Manip Ther. 2009;17(3):163–70.PubMedPubMedCentralCrossRef
42.
go back to reference McElhone K, Abbott J, Sutton C, Mullen M, Lanyon P, Rahman A, et al. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68(10):1505–13.PubMedPubMedCentralCrossRef McElhone K, Abbott J, Sutton C, Mullen M, Lanyon P, Rahman A, et al. Sensitivity to change and minimal important differences of the LupusQoL in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2016;68(10):1505–13.PubMedPubMedCentralCrossRef
43.
go back to reference Chen HH, Chen DY, Chen YM, Lai KL. Health-related quality of life and utility: comparison of ankylosing spondylitis, rheumatoid arthritis, and systemic lupus erythematosus patients in Taiwan. Clin Rheumatol. 2017;36(1):133–42.PubMedCrossRef Chen HH, Chen DY, Chen YM, Lai KL. Health-related quality of life and utility: comparison of ankylosing spondylitis, rheumatoid arthritis, and systemic lupus erythematosus patients in Taiwan. Clin Rheumatol. 2017;36(1):133–42.PubMedCrossRef
44.
go back to reference Chaigne B, Finckh A, Alpizar-Rodriguez D, Courvoisier D, Ribi C, Chizzolini C, et al. Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res. 2017;26(7):1767–75.PubMedCrossRef Chaigne B, Finckh A, Alpizar-Rodriguez D, Courvoisier D, Ribi C, Chizzolini C, et al. Differential impact of systemic lupus erythematosus and rheumatoid arthritis on health-related quality of life. Qual Life Res. 2017;26(7):1767–75.PubMedCrossRef
45.
go back to reference Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62.PubMedPubMedCentralCrossRef Golder V, Kandane-Rathnayake R, Hoi AY, Huq M, Louthrenoo W, An Y, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62.PubMedPubMedCentralCrossRef
46.
go back to reference Ugarte-Gil MF, Pons-Estel GJ, Vila LM, McGwin G, Alarcon GS. Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. RMD Open. 2019;5(1):e000955.PubMedPubMedCentralCrossRef Ugarte-Gil MF, Pons-Estel GJ, Vila LM, McGwin G, Alarcon GS. Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. RMD Open. 2019;5(1):e000955.PubMedPubMedCentralCrossRef
47.
go back to reference Ugarte-Gil MF, Gamboa-Cardenas RV, Reategui-Sokolova C, Medina-Chinchon M, Zevallos F, Elera-Fitzcarrald C, et al. Low disease activity state/remission predicts a better health-related quality of life in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2019. https://doi.org/10.1002/acr.24009 [Epub ahead of print]. Ugarte-Gil MF, Gamboa-Cardenas RV, Reategui-Sokolova C, Medina-Chinchon M, Zevallos F, Elera-Fitzcarrald C, et al. Low disease activity state/remission predicts a better health-related quality of life in systemic lupus erythematosus patients. Arthritis Care Res (Hoboken). 2019. https://​doi.​org/​10.​1002/​acr.​24009 [Epub ahead of print].
48.
go back to reference Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363–75.PubMedCrossRef Schmeding A, Schneider M. Fatigue, health-related quality of life and other patient-reported outcomes in systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2013;27(3):363–75.PubMedCrossRef
49.
go back to reference Bjordal K: Impact of quality of life measurement in daily clinical practice. Ann Oncol. 2004,15 Suppl 4:iv279–82.PubMedCrossRef Bjordal K: Impact of quality of life measurement in daily clinical practice. Ann Oncol. 2004,15 Suppl 4:iv279–82.PubMedCrossRef
50.
go back to reference McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995;4(4):293–307.PubMedCrossRef McHorney CA, Tarlov AR. Individual-patient monitoring in clinical practice: are available health status surveys adequate? Qual Life Res. 1995;4(4):293–307.PubMedCrossRef
Metadata
Title
Comparison of performance of specific (SLEQOL) and generic (SF36) health-related quality of life questionnaires and their associations with disease status of systemic lupus erythematosus: a longitudinal study
Authors
Worawit Louthrenoo
Nuntana Kasitanon
Eric Morand
Rangi Kandane-Rathnayake
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 1/2020
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/s13075-020-2095-4

Other articles of this Issue 1/2020

Arthritis Research & Therapy 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.